It appears more and more clear that retinoblastoma (RB) family of proteins represents key molecules in tumour suppression. This family consists of pRb/p105, p107 and pRb2/p130, which participate in a gene regulatory network that governs the cellular response to antimitogenic signals, and whose deregulation constitutes one of the hallmarks of cancer. Irrespective of their structural and biochemical similarities, RB proteins carry out different functional tasks. The expression of RB gene family in the reactive lymphoid tissues again confirms the different role of each member in cell cycle control and differentiation of normal cells. These different functional properties appear to be maintained in tumours lymphoid tissues, where alterations of the RB/p105 gene appear to be relatively rare. In this review, we will summarize the current knowledge about the role of the RB proteins in reactive and neoplastic lymphoid tissue.
Retinoblastoma gene family
Tumour suppressor genes represent a crucial milestone in the understanding of cancer genetics (Weinberg, 1995) . The RB/p105 gene is the prototypical tumour suppressor gene, and it was the first gene to be identified as a member of the retinoblastoma (RB) family. The RB family consists of pRb/p105, p107 and pRb2/p130, which are structurally and functionally correlated (Stiegler et al., 1998) . These proteins are central participants in a gene regulatory network that governs the cellular response to antimitogenic signals, and whose deregulation constitutes one of the hallmarks of cancer (Hanahan and Weinberg, 2000) . Retinoblastoma proteins are structurally and biochemically similar and they carry out similar functional tasks. Many of the sequence similarities reside in a homologous functional domain known as the pocket region; for this reason, these proteins are also referred to as 'pocket proteins'. In this region, pRb2/p130 and p107 are much more closely related to each other, with about 50% amino-acid identity, than they are to pRb/p105 (30-35% identity). The pocket region confers a peculiar steric conformation to the RB family members; it is responsible for many protein-protein interactions and characterizes the functional activity of these proteins in the homeostasis of the cell cycle (Ewen et al., 1991; Paggi et al., 1996) . A number of common targets have been found to interact with the pocket region, including members of the E2F/DP family of transcription factors, oncoproteins from DNA tumour viruses, the D-type cyclins and the histone deacetylases (Weinberg, 1995; Lee et al., 1998) . It is interesting to note that even though all three members share high homologies and overlapping features and activities, each protein has a unique function and plays a unique, non-redundant role (Claudio et al., 1996) . However, there might be scenarios in which they become redundant, as the mutational loss is functionally compensated for by that of another. Each member of the RB family elicits G1 growth arrest upon ectopic expression in sensitive cell lines, and their phosphorylation state is regulated in a cell cycledependent manner. Even with their many similarities, it is becoming evident that the RB family members are not fully functionally redundant, and p107 and pRb2/ p130 are not merely surrogates for pRb/p105. There are fundamental differences in the specific mechanisms of growth inhibition employed by these proteins (Claudio et al., 1994) . In several cell lines, including the human T98G glioblastoma cell line, which is resistant to the suppressive effects of both pRb/p105 and p107, pRb2/ p130 mediates a G0/G1-phase cell cycle arrest. Additionally, modulation of the phosphorylation state of the RB family members varies among family members when associated with certain viral oncoproteins. The regulation of all three members is complex and unique. Regulation of all of the three genes occurs at the transcriptional as well as the post-transcriptional level (Smith et al., 1996 (Smith et al., , 1998 . Although pRb/p105, p107 and pRb2/p130 are similar in sequence and protein structure, they differ in the timely expression pattern detected in different tissues. pRb/p105 is abundant at all times, whereas p107 is most prominent in proliferating cells and pRb2/p130 is preferentially expressed in arrested cells (Classon and Dyson, 2001 ). Regulation of their biological activity is exerted by changes in their phosphorylation status. The proteins are active in their hypophosphorylated form, in which they bind to the E2F transcription factors and inhibit the E2F transactivation domain. Increasing phosphorylation of the proteins will inactivate pRBs, which will be then degraded, leading to the release of the E2Fs and allowing the expression of genes that mediate S-phase entry (Flemington et al., 1993; Helin and Ed, 1993) . The sites of phosphorylation of pRBs are targeted by cyclin/ CDK complexes specifically induced during different stages of G1/S progression. Cyclin/CDK-mediated phosphorylation of pRBs is likely to be the mechanism by which the biological activity of these proteins is turned off during the G1/S transition and the following phases of the cell cycle. pRBs exert their growth suppressive properties by regulating a number of downstream effectors (Kouzarides, 1995) .
Crosstalk between retinoblastoma family and cell cycle regulatory proteins
The best-characterized pRB targets are the members of the E2F/DP family of transcription factors. Several members belong to this family, E2F1-7 and DP1-2, with distinctive binding properties to pRBs (for a review see Cobrinik, 2005) . Within the E2F family, E2F1, 2 and 3 are strong transcriptional activators that are preferentially bound and inhibited by pRb/p105. E2F1-3 are generally absent or expressed at low levels in quiescent cells, and are induced at high levels and stimulate gene expression in late G1 (Dyson, 1998) . E2F4 and 5 bind to pRb2/p130 and p107. They are expressed throughout the cell cycle, but in G0 and in early G1 they are bound and recruited to the nucleus by pRb2/p130 and p107 and form transcriptional repressor complexes with them. E2F6 and E2F7 do not bind to pocket proteins and repress E2F-responsive genes through other means (Dimova and Dyson, 2005) . Pocket proteins mediate G0/G1 arrest through their repression of E2F-regulated genes. They are believed to accomplish this by recruiting a variety of chromatin-modifying activities to E2F-responsive promoters (Frolov and Dyson, 2004) . Pocket proteins recruit type I histone deacetylases (HDACs), resulting in removal of acetyl groups from histones H3 and H4, and in a compacted chromatin structure that is refractory to transcription initiation (Takahashi et al., 2000; Rayman et al., 2002) . The recruitment of HDACs is indirect (Lai et al., 2001) and accompanied by recruitment of other co-repressors, chromatin remodelling factors and histone methyltransferases (Frolov and Dyson, 2004) . The specific interaction of E2Fs and pocket proteins, together with their distinct expression, subcellular localization and promoter-binding partners, has suggested several related models of the pocket protein-E2F network (Stevaux and Dyson, 2002; Trimarchi and Lees, 2002; Cam and Dynlacht, 2003) . The model provides for several different states of E2F-responsive promoters in the different cell cycle phases. In G0 and in early G1, p107 and pRb2/p130 form repressor complexes in conjunction with E2F4 or E2F5 at most, if not all, E2F-responsive promoters. Meanwhile, pRb/p105 is thought to bind to E2F1-3 either at, or sequestered away from, such promoters.
In late G1, pocket proteins are generally phosphorylated and dissociate from E2Fs. E2F4 and E2F5 then relocate to the cytoplasm, and the promoters generally bind to E2F1-3. For many promoters, the binding of E2F1-3 correlates with recruitment of histone acetyltransferases, increased histone acetylation and transcriptional activation (Takahashi et al., 2000; Rayman et al., 2002; Taubert et al., 2004) . A model for pRb2/p130 and p107 control during cell proliferation has been proposed based on experimental data. In quiescent G0 cells, the nuclear E2F-pRb2/p130 complex is responsible for the active repression of a number of cellular promoters. When cells need to proceed through the cell cycle, pR2/p130 is subsequently phosphorylated by cyclin D/CDK4, 6 and cyclin E/CDK2 complexes and then degraded through a proteasome-dependent mechanism. Following its increased expression, cyclin D1 initiates cell cycle progression towards S phase. The main role of cyclin D1 consists in its association with CDK4 to initiate pRB phosphorylation (Ewen et al., 1991; Dowdy et al., 1993) , relieve HDAC binding and finally allow access of cyclin E/CDK2 complexes to their target. pRB hyperphosphorylation disrupts its association with E2F and allows transcriptional activation of the S-phase genes, including the cyclin E gene. Interestingly, cells that have lost RB no longer require cyclin D1 to proliferate (Bartek et al., 1996) , suggesting that pRB phosphorylation, E2F activation and most importantly the corresponding cyclin E expression are probably important functions of cyclin D1/CDK4 in cell cycle regulation. Moreover, E2F is unable to induce S-phase entry in the absence of cyclin E activity, indicating that cyclin E is probably an activator of E2F but also a downstream effector. The outcome of these studies suggests that cyclin E may have E2F-independent functions that can bypass the need for pRB inactivation. In line with the hypothesis that cyclin E is one of its important targets, cyclin D1 activates the kinase activity of the cyclin E/CDK2 complex by a second mechanism that is independent of the E2F-mediated activation of the cyclin E promoter.
Cyclin/CDK complexes are regulated by CDK inhibitors (CKIs), which modulate their biological activity. There are two families of CKIs: INK4 and CIP/KIP. The INK4 family consists of p16, p15, p18 and p19; these proteins specifically inhibit cyclin D-associated kinases. The structural basis for the inhibition of CDK4/6 kinase activity by INK4 proteins has been well established. The four INK4 proteins share a structural motif, the ankyrin repeats, that consists of pairs of antiparallel K helices, stacked side by side and connected by a series of intervening hairpin motifs. These structural domains are involved in binding to the non-catalytic side of CDK4 and CDK6, opposite the cyclin D-binding site. By preventing the formation of CDK4, 6/cyclin D complexes, INK4 proteins also force the redistribution of Cip/Kip inhibitors to the CDK2/ cyclin E complexes, causing downregulation of this kinase (Sherr and Roberts, 1999) .
The Cip/Kip family is constituted by p21, p27 and p57; these members target the cyclin E/CDK2 and cyclin A/CDK2 complexes. Cip/Kip proteins interact with cyclin/CDK complexes through their N-terminal part to inhibit their kinase activity and block cell cycle progression. Surprisingly, the vast majority of cyclin/ CDK exist in ternary complexes containing p21, and some p21/CDK-containing complexes are found in an active form (LaBaer et al., 1997) . In proliferating cells, most Kip proteins are complexed to cyclin D/CDK4 complexes but not to cyclin E/CDK2, suggesting that cell proliferation is dependent on free CDK2 complexes but can tolerate CDK4 complexes bound to Kip/Cip proteins. It is now believed that the initial raise of cyclin D1 serves to compete with cyclin E for Cip/Kip binding and to lower the level of these inhibitory proteins bound to CDK2. During G1 progression, titration of Cip/Kip proteins into appearing cyclin D/CDK4 complexes progressively relieves cyclin E/CDK2 from their inhibitory effect, thereby inducing CDK2 activity and progression towards S phase. When mitogens are removed, transcriptional inhibition of the cyclin D1 promoter and ubiquitination of the protein induces the release of the bound Cip/Kip proteins, CDK2 inhibition and cell cycle blockade. The important conclusion is that once cyclin E becomes activated, cyclin D1 is probably dispensable for cell cycle progression.
Deregulation of each member of the pathway that controls pRB phosphorylation may represent a key step in tumorigenesis.
There has been increased evidence of the oncosuppressive activity of pRBs, as different mechanisms of inactivation of these genes have recently been demonstrated to play a role in various human neoplasms. Several mutations in the genes have been found, resulting in modification of the primary protein structure and consequently strongly impairing their functions. Epigenetic events, such as promoter hypermethylation, may be responsible for gene silencing and may impair the biological activity of these proteins. Besides genetic and epigenetic mechanisms of RB family inactivation, interaction with viral oncoproteins is another important mechanism of inactivation of pRBs, as oncoviral disruption of E2F/DP complexes induces E2F site-dependent transcription, resulting in permanent cell cycle progression (see also White and Khalili, in this issue). Many viral oncoproteins have been shown to bind to the pocket region of pRBs and, by this mechanism, cause inactivation of their tumour suppression function and enhance neoplastic progression. In particular, early-acting viral antigens of DNA viruses, such as E1A and SV-40 large T antigen, specifically target the RB family of proteins and these viruses force infected cells into DNA synthesis, thereby emphasizing the crucial growth-suppressive properties of the RB gene family (Bartek et al., 1992; Putzer et al., 1997) .
Retinoblastoma gene family in reactive lymphoid tissues
In reactive lymphoid tissues, each RB family protein has a peculiar pattern of expression. Immunohistochemical stain for the Rb/p105 expression in reactive lymphoid tissues has revealed that there is an intense staining of germinal centre cells, with strongest staining in the centroblasts of the proliferating (dark) zone and weak or undetectable staining of the small lymphocytes in the mantle zone and interfollicular region. Faint or undetectable staining was also found in the interfollicular T cells and cortical thymocytes (Zukerberg et al., 1996) . This staining pattern for Rb/p105 indicates that there is a clear correlation with the expression of the Ki67, a proliferation marker. Furthermore, it has been demonstrated that normal and stimulated lymphocytes show a gradual increase of pRb/p105 protein during progression of the cell cycle, with a peak in the M phase (Zukerberg et al., 1996) . These findings suggest that pRb/p105 expression in lymphoid cells may be related to the stage of differentiation, being preferentially expressed in cells that are at the interface between proliferation and differentiation. The absence of staining in resting lymphoid cells does not indicate that these cells lack a functional RB/p105 gene, only that its product is expressed at levels below the detection limits of staining.
Less is known about the expression of p107 and pRb2/p130 in normal lymphoid tissues. However, there is evidence that the expression of p107 in reactive lymph nodes is comparable to that of pRb/p105, whereas pRb2/p130 expression is found in small resting lymphoid cells and lost in proliferating blast of germinal centre. This may well suggest that the proliferation of lymphoid cells is mainly regulated by RB2/p130 rather than p107 and RB/p105 (Leoncini et al., 1999) .
Retinoblastoma gene family in tumours of lymphoid tissues
Hodgkin's lymphoma Hodgkin's lymphoma (HL) is a distinct primary solid malignancy of the immune system in which the exuberant production of cytokines and chemokines is associated with an abundance of a component of inflammatory cells that outnumber the recognized tumoral sub-population of Hodgkin and Reed-Sternberg (H/RS) cells. These H/RS cells harbour clonally rearranged and somatically mutated immunoglobulin genes, indicating that they are derived from germinal centre B cells in most cases (Garcia et al., 2003) . On analysing expression of pRb/p105 in Hodgkin's disease samples, a clear difference emerges between cases of nodular lymphocyte predominance, which preserve the relationship between pRb/p105 and Ki67 expression, features similar to reactive lymphadenitis, and classical forms of Hodgkin's disease (nodular sclerosis and mixed cellularity), which display a strong deviation from this pattern. In classical Hodgkin's disease, two main anomalies were found: (1) one group with partial or total loss of pRb/p105 protein expression, which could reflect the existence of genetic alterations, or an altered transcriptional or translational regulation of the RB/p105 gene. (2) Another group with an abnormally high pRb/p105/Ki67 ratio, which could be subject to conflicting interpretations: (i) excess pRb/p105 protein to control cell cycle progression; or (ii) adhesion of the pRb/p105 protein to other cellular or viral proteins, such as p53 and MDM2. This may suggest that there is an anomalous pattern of expression of pRb/p105 in some cases of classical forms of Hodgkin's disease (Sanchez-Beato et al., 1996) .
In addition, recent analyses using tissue microarrays have demonstrated that in most cases, Hodgkin and Reed-Sternberg cells display deregulation of the genes involved in the G1/S and G2/M checkpoints, and inactivation of the tumour suppressor pathways defined by p14-p53-p21, p16-pRb/p105, and p27. In particular, the p16-Rb pathway is also presumably inactivated in a large fraction of these samples as the result of p16 INK4a loss (owing to promoter region methylation or deletion) and/or cyclin D overexpression (Garcia et al., 2003) .
Non-Hodgkin's lymphoma
Lymphoid neoplasms represent a broad variety of disease states composed of clonally expanded populations of T or B lymphocytes. The discovery of activation of genes in lymphoid neoplasms, particularly as a consequence of chromosomal translocation, has focused attention on the role of oncogene products and other growth-promoting cellular constituents in the pathogenesis of these diseases. However, limited information still exists regarding the possible role of inactivation of tumour suppressor genes in lymphoma or leukaemia.
The normal regulation of pRb/p105 in relation to proliferative activity is frequently preserved in different types of lymphoma, in which genetic alterations of the RB/p105 gene appear to be relatively rare. Levels of pRb/p105 are low in low-growth fraction non-Hodgkin's lymphomas (NHLs), whereas they are higher in most high-growth fraction tumours (Sanchez-Beato et al., 2003) . A positive correlation between the expression of p107 and proliferative features such as mitotic index and percentage of Ki67 and cyclin A cells has also been demonstrated in a large series of NHL, whereas such a correlation could not be demonstrated for the percentages of pRb2/p130-positive cells (Leoncini et al., 1999) . In fact, low immunohistochemical levels of pRb2/p130 in untreated patients with NHLs of various histotypes inversely correlated with a large fraction of cells expressing high levels of p107 and proliferation-associated proteins. Such a pattern of protein expression is normally observed in continuously cycling cells. Interestingly, these cases showed the highest survival percentage at the end of 10 years of observation. Thus, downregulation of the RB-related pRb2/p130 protein could be one of the reasons why these cases display such a high rate of proliferation and why they respond so well to therapy (Leoncini et al., 1999) .
In particular, low levels of pRb/p105 are found in B-cell chronic cymphocytic lenkaemia(B-CLL);
although B-CLL cells are arrested in G0/early G1 phase of the cell cycle, it seems to be the effect of the strong upregulation of both cyclin D2 and cyclin D3 found in B-CLL rather than a mutation of pRb/p105 function (Decker et al., 2002) . Furthermore, pRb/p105 is normally regulated in Mantle cell lymphoma (MCL), but this lymphoma is molecularly characterized by bcl-1 rearrangement and constant cyclin D1 (PRAD-1/CCND1) gene overexpression. Cyclin D1 overexpression plays a role in the maintenance of cell proliferation by overcoming the suppressive growth control of pRb/p105 (Jares et al., 1996) . However, in transgenic mice, the overexpression of cyclin D1 alone is not sufficient for the development of a malignant lymphoma, suggesting that other members of the pRb/p105 pathway contribute to the malignant transformation of MCL. Recent findings suggest that deletion of CDKN2/p16, which occurs in approximately one-half of MCLs, is a more relevant indicator of the proliferative features as compared to morphological criteria (Dreyling et al., 1997) .
Large B-cell lymphoma (LBCL) have frequent disruption of the RB pathway with a mutually exclusive pathway between cyclin D3 overexpression and p16/ pRb/p105 aberrations (Moller et al., 2000) . In addition, a tendency for concurrent alterations of the cell cycle regulators p27, p53 and p16 in LBCL has been reported, which might result in impaired tumour growth control. Indeed, the analysis of the combined p27/p53/p16 expression status with respect to the proliferation profile showed combined impairment of a complex cell cycle control network involving the CDK inhibitor p27, the p53 pathway and the RB pathway, which exerts a cooperative effect resulting in enhanced tumour cell proliferation. Recent work points to an association between high levels of cyclin D3 expression and poor clinical outcome in LBCL. It is interesting to note that, in addition to the direct activation of CDK4/6, cyclin D3 appears to play another role in the promotion of cell proliferation, that is, the indirect activation of CDK2-cyclin E achieved by the sequestration of p27. In this context, p27 might be protected from CDK2-mediated degradation and at the same time be inactive as a CKI, because CDK4-cyclin D-KIP complexes appear to preserve kinase activity (Erlanson et al., 1998) .
Burkitt's lymphoma (BL) is an Epstein-Barr virusassociated malignancy, with endemic BL (eBL) occurring among children in the malaria belt of equatorial Africa and sporadic BL (sBL) occurring in other geographical areas, also among adults. pRb/p105 in BL is frequently normally expressed, but again the RB pathway is inactivated in a large fraction of BL. In fact, p16 inactivation by promoter methylation or by homozygous deletion or point mutations has been observed in most cases of BL (Lindstrom and Wiman, 2002) . In addition, reports showing that the pRb-related protein pRb2/p130 is mutated in its nuclear localization signal in BL lines and primary tumours raise the possibility that inactivation of this member of the pRB family renders BL cells more susceptible to transformation by activated c-Myc (Cinti et al., 2000) . Interaction between p107 and c-myc has been demonstrated and during lymphomagenesis missense mutations of c-Myc may be selected because the mutant Myc protein has altered interactions with p107 (Hoang et al., 1995) .
Furthermore, analysis of AIDS-related lymphomas other than BL showed no mutations in the RB2/p130 gene and unusually high percentages of cells expressing nuclear pRb2/p130 in all AIDS-related lymphomas with a high proliferative activity. These findings suggest that a molecular mechanism usually observed in viral-linked oncogenesis could be involved. In fact, it has been demonstrated that the human immunodeficiency virus (HIV) gene product Tat physically binds to pRb2/p130, blocking its oncosuppressive activity (Lazzi et al., 2002) .
Other haematopoietic and lymphoid malignancies
In haematological malignancies, deletion of p16 and p15 locus has been shown to be highly specific to lymphoid malignancies, and more specifically to T-cell acute lymphoblastic leukaemia (T-ALL). In these malignancies, pRb/p105 may play an essential role in its hypophosphorylated form for progression of T-ALL, as well as a cell cycle promoter in hyperphosphorylated or negative/excessive reduced form (Nakayama et al., 2000) . However, in the other subsets of acute lymphoblastic leukaemia (ALL), deletions of p16 and p15 are relatively rare events. Recent studies have demonstrated frequent methylation of p16 and p15 genes in B-ALL and acute myeloid leukaemia (AML) despite a low frequency of p16 and p15 deletions and mutations in these leukaemias. In addition, the expression of pRb/ p105 is very rare in leukaemia cell lines, suggesting that inactivation of p16 and p15 genes is one of the most common genetic events in acute leukaemia, and plays an important role for the pRb/p105-p16 pathway in the pathogenesis of acute leukaemia (Guo et al., 2000) .
Studies of plasma cell malignancies showed that Ki67 expression in multiple myeloma (MM) increased in parallel with p16 and pRb/p105 expression. In this malignancy, the pRb/p105 expression could represent a growth control response, which, however, may not be able to induce growth arrest in view of the parallel increase in Ki67 expression and of previous findings showing that pRb/p105 protein in MM cells is mostly expressed in its phosphorylated form. Cyclin D1 locus alterations and pRb/p105 deletions were associated with a significantly worse prognosis, whereas p16 hypermethylation had no impact on survival. This suggests that cyclin D1 and pRb/p105 aberrations seem to occur as alternative events in plasma cell malignancies and contribute to clinical course and prognosis. In contrast, although p16 hypermethylation is frequent, inactivation of p16 seems not to be involved in the pathogenesis of plasma cell disorders (Kramer et al., 2002) .
Conclusion
The expression of RB gene family in the reactive lymphoid tissues again confirms the different role of each member in cell cycle control and differentiation of normal cells.
In fact, the pattern of expression in reactive lymphoid tissues suggests that pRb/p105 expression may be related to the stage of differentiation, being preferentially expressed in cells that are at the interface between proliferation and differentiation. On the other hand, pRb2/p130 rather than p107 and pRb/p105 seems to be involved in the control of proliferation in lymphoid cells.
These different functional properties appear to be maintained in tumours of lymphoid tissues, where alterations of the RB/p105 gene appear to be relatively rare. On the other hand, alterations have often been found in the pRB pathway involving p16, p21 and p27, as a consequence of genetic and/or epigenetic alterations of those particular genes but also of mutations of the other RB-related genes.
However, despite the important progress that has been made towards elucidation of the mechanisms of lymphomagenesis, many points still need to be clarified and prompt further investigation to better understand the role of RB gene family in the initiation and progression of lymphomas.
